KR20130016794A - Composition for improving lipid metabolism disease - Google Patents

Abstract

PURPOSE: A food composition and a pharmaceutical composition containing a Salicornia herbacea L. extract, a Patrinia scabiosaefolia extract, or a mixture thereof are provided to reduce body fat and neutral fat and to prevent cardiovascular diseases and diabetes. CONSTITUTION: A food composition for treating lipid metabolic diseases contains a Salicornia herbacea L. extract, a Patrinia scabiosaefolia extract, or a mixture thereof as an active ingredient. The lipid metabolic diseases are obesity, hyperlipidemia, arteriosclerosis, or fatty liver. A pharmaceutical composition for preventing or treating the lipid metabolic diseases contains the Salicornia herbacea L. extract, the Patrinia scabiosaefolia extract, or a mixture thereof as an active ingredient. The extract is prepared using a polar solvent or a non-polar solvent.

Description

[0001] The present invention relates to a composition for improving lipid metabolism disease,

The present invention relates to Salicornia herbacea L.) extracts, paejang (Patrinia scabiosaefolia ) extract or a mixture thereof as an active ingredient.

In Korea, the incidence of adult diseases such as obesity, diabetes, hypertension and arteriosclerosis is increasing due to rapid economic growth, improvement of income level, change of eating habit and decrease of physical activity. The World Health Organization estimates that about 1.6 billion adults are overweight and that at least 400 million people are obese. When the obesity rate was over 25 ㎏ / ㎡ in Korea, the proportion of obese people over 20 years old was 30.6% in 2001 and 31.8% in 2005.

Obesity has attracted a great deal of attention worldwide because it can cause diseases such as cardiovascular disease, diabetes, respiratory disease and osteoarthritis, as well as the problems it has in itself. Obesity is a combination of neuroendocrine, drug-induced, and genetic factors as well as over-consumption of energy and lack of exercise, so dietary, exercise, behavioral therapy and medication are used to improve obesity . However, drug therapy is accompanied by adverse effects such as oil stomach, abdominal bloating, dizziness, gaggles, constipation, and elevated blood pressure. Therefore, studies have been actively carried out to find functional materials effective for weight control from natural plants, have.

Salicornia herbacea L. is a perennial plant belonging to the genus Chenopdiaceae , native to the coastal waters of the south coast of Korea and the coastal waters of the west coast of Korea. It is also known as the 'Tungtungmadi'. In order to withstand the osmotic pressure in the salt marsh plant, the tidal-flat plant, which is a tidal-flat plant, contains a large amount of natural minerals such as Mg, Ca, Fe and K as well as a large amount of salt in the plant. It is also rich in essential amino acids and essential fatty acids, and contains a large amount of dietary fiber, and is also used as a medicinal product for succulence, constipation, indigestion, gastroenteritis, hepatitis and kidney disease. And flavonoid components of β-sitosterol, stigmasterol, uracil and isorhamnetin-3-O-β-D-glucopyranoside are separated and antioxidant activity It turned out. It is known that green tea is effective for cancer, sinusitis, arthritis, hypertension, back pain, obesity, hemorrhoids, diabetes, thyroiditis, asthma, bronchitis and liver disease. However, It is true.

The purpose of this study was to investigate the physiological effects such as suppression of obesity and diet effects of green tea extract by feeding the green tea extract to the obese - induced rats fed with the feed and observing the factors related to the obesity inhibition in the blood.

Numerous papers and patent documents are referenced and cited throughout this specification. The disclosures of the cited papers and patent documents are incorporated herein by reference in their entirety to better understand the state of the art to which the present invention pertains and the content of the present invention.

The present inventors have sought to develop natural products having an effect of improving lipid metabolism diseases. As a result, the present invention was completed by confirming that the green tea extract, cabbage extract or a mixture thereof is excellent in improving lipid metabolism diseases.

It is therefore an object of the present invention to provide a pharmaceutical composition for the prevention or treatment of lipid metabolic diseases.

Other objects and advantages of the present invention will become more apparent from the following detailed description of the invention, claims and drawings.

According to one aspect of the present invention, there is provided a food composition for improving lipid metabolism diseases, comprising a green tea extract, a cabbage extract or a mixture thereof as an active ingredient.

The present inventors have sought to develop natural products for the improvement of lipid metabolism diseases. As a result, it was found that the extract of green tea, extract of cabbage, or a mixture thereof showed excellent improvement of lipid metabolism diseases.

The term " extract " used herein to refer to green onions and cabbages is used to refer to a product that is formulated (for example, powdered) so that it can be administered to an animal as well as the extraction result obtained by treating the green tea or cabbage with the extraction solvent It also has the meaning that it includes green tea and fruit shells.

When the green tea extract and cabbage extract used in the composition of the present invention are obtained by treating an extract solvent of green tea or cabbage, various extraction solvents may be used. Preferably, a polar solvent or a nonpolar solvent can be used. Suitable polar solvents include (i) water, (ii) alcohols (preferably methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, normal-butanol, 1-pentanol, 2-butoxyethanol Or ethylene glycol), (iii) acetic acid, (iv) dimethyl-formamide (DMFO) and (v) dimethyl sulfoxide (DMSO). Suitable as nonpolar solvents are acetone, acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, hexane, 2,2,4-trimethylpentane, decane, cyclohexane, cyclopentane, diisobutylene, 1- Pentene, 1-chlorobutane, 1-chloropentane, o-xylene, diisopropyl ether, 2-chloropropane, toluene, 1-chloropropane, chlorobenzene, benzene, diethyl ether, diethyl sulfide, chloroform, dichloro Methane, 1,2-dichloroethane, anneal, diethylamine, ether, carbon tetrachloride and THF (Tetrahydrofuran).

More preferably, the extraction solvent used in the present invention is (a) water, (b) anhydrous or hydrous lower alcohol having 1 to 4 carbon atoms (methanol, ethanol, propanol, butanol, etc.), (c) the lower alcohol and water Mixed solvent with (d) acetone, (e) ethyl acetate, (f) chloroform, (g) butyl acetate, (h) 1,3-butylene glycol, (i) hexane and (j) diethyl ether Include. Most preferably, the extract of the present invention is obtained by treating water, ethanol, methanol or propanol with green tea or fennel.

Preferably, the composition of the present invention comprises a mixture of Leek extract and cabbage extract.

As used herein, the term "extract" has the meaning commonly used as a crude extract in the art as described above, but also broadly includes a fraction additionally fractionating the extract. Namely, the green tea extract and cabbage extract are obtained not only by using the above-mentioned extraction solvent but also by additionally applying a purification process thereto. For example, a fraction obtained by passing the above extract through an ultrafiltration membrane having a constant molecular weight cut-off value, and a separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity) The fraction obtained by the purification method is also included in the green tea extract and the cabbage extract of the present invention.

The leeks extract and cabbage extract used in the present invention can be prepared in powder form by an additional process such as vacuum distillation and freeze drying or spray drying.

As used herein, the term "comprising as an active ingredient" means an amount sufficient to achieve the efficacy or activity of the following fruits and vegetables. Since the present invention is a composition extracted from natural plant material such as green tea and cabbage, there is no adverse effect on the human body even when administered in an excessive amount. Therefore, the quantitative upper limit of the composition containing the green tea extract, rosacea extract or a mixture thereof is appropriately selected by a person skilled in the art .

The diseases prevented or treated by the present invention are lipid metabolic diseases. The lipid metabolic diseases include diseases associated with bile acid, cholesterol, icosanoids, glycolipids, ketone bodies, fatty acids, phospholipids, sphingolipids, steroids and triacylglycerol.

Preferably, the lipid metabolic diseases to be prevented or treated by the composition of the present invention are obesity, hyperlipidemia, arteriosclerosis and fatty liver.

As evidenced in the following examples, in rats that induced obesity in a high fat diet, body weight was reduced in the group that consumed a diet containing a Leish extract, a cabbage extract, or a mixture thereof. In addition, the amount of epididymal fat and kidney lipid, which represent body fat accumulation, was significantly decreased in the group fed with the green tea extract, cabbage extract or a mixture thereof, and the atherogenic index was decreased by analyzing the blood lipid component Respectively.

The food composition of the present invention may contain, as an active ingredient, a green tea extract and a cabbage extract, as well as a component that is ordinarily added during the manufacture of a food, for example, a protein, a carbohydrate, a fat, a nutrient, a seasoning agent, . Examples of the above carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol. As flavoring agents, natural flavoring agents (tauumatin, stevia extract (for example rebaudioside A, glycyrrhizin, etc.)) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used. For example, when the food composition of the present invention is prepared as a drink, it may contain citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, juice, mulberry extract, jujube extract, licorice extract, etc., Can be further included.

According to another aspect of the present invention, there is provided a pharmaceutical composition for preventing or treating fat metabolism diseases, comprising a green tea extract, a cabbage extract or a mixture thereof as an active ingredient.

The pharmaceutical composition of the present invention includes a pharmaceutically acceptable carrier. The pharmaceutically acceptable carrier is conventionally used in the preparation, lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia rubber, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, Polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil, and the like. In addition to the above components, the pharmaceutical composition of the present invention may further include a lubricant, a humectant, a sweetener, a flavoring agent, an emulsifier, a suspending agent, a preservative, and the like. Suitable pharmaceutically acceptable carriers and formulations are described in detail in Remington ' s Pharmaceutical Sciences (19th ed., 1995).

The pharmaceutical composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, and preferably, oral administration. .

Suitable dosages of the pharmaceutical compositions of the invention vary depending on factors such as the formulation method, mode of administration, age, weight, sex, morbidity, condition of food, time of administration, route of administration, rate of excretion and response to reaction, Usually a skilled practitioner can easily determine and prescribe a dosage effective for the desired treatment or prophylaxis. According to a preferred embodiment of the present invention, the daily dose of the pharmaceutical composition of the present invention is 0.001-10000 mg / kg.

The pharmaceutical composition of the present invention may be formulated into a unit dose form by formulating it using a pharmaceutically acceptable carrier and / or excipient according to a method which can be easily carried out by a person having ordinary skill in the art to which the present invention belongs. Or by intrusion into a multi-dose container. The formulations may be in the form of solutions, suspensions or emulsions in oils or aqueous media, or in the form of excipients, powders, granules, tablets or capsules, and may additionally contain dispersing or stabilizing agents.

The features and advantages of the present invention are summarized as follows:

(a) The present invention provides a food composition and a pharmaceutical composition for improving lipid metabolism diseases.

(b) The composition of the present invention can reduce body fat and triglycerides and reduce the risk of arteriosclerosis.

(c) The composition of the present invention can be used to improve lipid metabolism diseases and prevent cardiovascular diseases and diabetes.

Hereinafter, the present invention will be described in more detail with reference to Examples. It is to be understood by those skilled in the art that these embodiments are only for describing the present invention in more detail and that the scope of the present invention is not limited by these embodiments in accordance with the gist of the present invention .

Example

Materials and methods

Experimental material

The sample used in the experiment was the green tea extract supplied from Dasarang Co., Ltd. The extracts of the green tea were extracted with hot water for 9 hours by adding 80 L of drinking water to 20 ㎏ of Hamcho hay. The first extract was filtered after the second heating for 3 hours. In addition, 10 ㎏ of cabbage extract was added with 10 L of drinking water to extract hot water for 9 hours, and the first extract was filtered after 3 hours of secondary heating. The above-mentioned fruit extract and cabbage extract were mixed at a weight ratio of 1: 1. The thus-prepared sample was again used as a test sample after being concentrated under reduced pressure at 80 ° C using a COSMOS-660 ultra-high vacuum low-temperature extraction concentrator (Kyungsung, Korea).

Experimental animal

Forty-eight male Sprague-Dawley (SD) male Sprague-Dawley rats (7 weeks old) were purchased from NARA Bio Co., Ltd., and the animals were adapted to the general diet for 1 week and induced for 6 weeks. The temperature and humidity of the animal breeding room were adjusted to 22 ± 0.5 ℃ and 55 ± 5%, respectively. After a week of adaptation period, obesity was further induced for 6 weeks, divided into normal control group and empirical group, and randomized complete block design was applied and the experimental diet was fed for 6 weeks.

Empirical formula

The experimental diets were prepared so that the test extract was 1% of the dietary weight based on AIN-76A. The test group consisted of the normal diet (N), the normal diet + 1% test extract (NS), the normal diet after induction of obesity (HN) (HH) and high fat diet after induction of obesity + 1% test extract group (HHS) were classified into 6 groups (Table 1). N is the jeongsangsik, that is the group ⁽¹⁾ fed the AIN-76A, HN means a group ⁽²⁾ switching to the normal diet after the induction of obesity, 10% fat in the high fat diet containing 45% fat.

Diet Dietary condition N ¹ Ingested group NS 1% normal diet group containing test extract HN After inducing obesity jeongsangsik intake group ² HNS A diet containing 1% test extract after induction of obesity HH High fat diet group HHS High-fat diet containing 1% test extract

Experimental equations for each group and microfilter were used to free the filtered groundwater. Dietary intake (g / day) was calculated by taking daily intake of dietary food at weekly intervals, and body weight was measured once a week. The food efficiency ratios of each experimental group were calculated by dividing the weight gain during the experimental period by the dietary intake during the same period.

Experimental animal sacrifice and organ harvesting

After 6 weeks of the experiment, the animals were fasted for 12 hours and blood was collected from the orbit and sacrificed by cervical dislocation. Blood was refrigerated for 1 hour, centrifuged at 4 ° C for 15 minutes at 3000 rpm (tabletop centrifuge, Hanil Scientific, Korea), and serum was stored frozen at -80 ° C until analysis and analysis. Liver, kidney, spleen, kidney, and epididymal fat were removed, washed with physiological saline, and the surface moisture was completely removed and weighed.

Biochemical analysis of blood

Serum total cholesterol, triglyceride, HDL-cholesterol, creatinine, aspartate aminotransferase (GOT) and alanine aminotransferase (GPT) were analyzed with an automated hematology analyzer (ADVIA 1650, Bayer Co., Japan). Serum insulin and leptin were measured using rat insulin ELISA (Mercodia, Sweden) and rat leptin ELISA (Biovendor, Czech Republic).

The atherogenic index (A.I.) and the cardiac risk factor (C.R.F.) were calculated by the following formula.

A.I. = (Total cholesterol-HDL cholesterol) / (HDL cholesterol)

CRF = (total cholesterol) / (HDL cholesterol)

Statistical processing

The results were expressed as the mean ± standard error of each test group using the SPSS (Statistical Package for Social Science Version 18.0) statistical program, and the significance between the test groups was tested at the level of p <0.05 using the independent sample T test.

Results and Discussion

Weight change and Dietary efficiency

After 6 weeks of obesity induction, a significant difference was found between the group fed the normal diet and the group fed the high - fat diet. After confirming that the group fed with high fat diet had a significant difference from the group fed the normal diet, HN, HNS, HH and HHS. The results of the weight gain of each group are shown in Tables 2 to 4. Table 2 shows the results of intake of the green tea extract as the test extract. Table 3 shows the results of the test extracts of the cabbage extract and Table 4 shows the initial weight, the weight gain, the dietary intake and the dietary efficiency . Changes in dietary intake were not significantly different between normal and obese subjects.

During the experimental period, the body weights of the experimental animals did not show a significant difference in the normal group, but in the obese induction group, the HNS group was 544.98 ± 14.22 g, which was significantly lower than the 596.05 ± 15.10 g in the HN group and 567.05 ± 6.43 g, which was significantly lower than that of 600.74 ± 10.67 g of HH group. Dietary efficiency was 0.14 ± 0.01 g in the NS group and 0.11 ± 0.00 g in the N group.

group Initial weight
(g) Final weight
(g) Weight gain
(g) Dietary Intake
(g / day) Dietary efficiency (FER) N 454.04 + - 11.01 558.75 ± 14.87 98.34 + - 4.34 23.97 + - 0.56 0.11 ± 0.00 NS 452.74 + 9.03 555.62 + - 14.09 100.03 + - 5.50 22.96 + - 0.45 0.14 ± 0.01 HN 489.87 ± 15.71 596.05 ± 15.10 77.62 + - 6.79 21.64 ± 0.45 0.10 ± 0.01 HNS 487.49 + - 7.85 544.98 +/- 14.22 ^* 78.98 + - 6.84 20.73 + - 0.34 0.10 ± 0.01 HH 487.06 + - 8.90 600.74 + - 10.67 106.72 + - 4.82 21.65 ± 0.39 0.15 ± 0.01 HHS 486.37 + - 8.52 567.05 ± 6.43 ^* 101.72 + 5.05 21.49 + - 0.37 0.14 ± 0.00

group Initial weight
(g) Final weight
(g) Weight gain (g) Dietary Intake
(g / day) Dietary efficiency
(FER) N 453.03 + - 11.04 557.85 +/- 14.87 104.82 ± 3.83 22.37 + - 0.56 0.12 ± 0.00 NS 457.74 ± 9.05 555.62 + - 14.09 97.88 + 5.04 22.95 + - 0.45 0.14 ± 0.01 HN 489.87 ± 15.77 586.05 ± 15.10 96.18 + - 0.67 25.64 + - 0.45 0.11 ± 0.01 HNS 487.99 ± 7.85 564.21 + - 14.22 ^* 76.22 + - 6.37 23.98 + - 0.34 0.12 ± 0.01 HH 489.74 + - 3.90 613.74 + - 10.67 124 ± 6.77 22.75 ± 0.40 0.13 ± 0.01 HHS 483.36 + - 8.72 589.04 + - 6.43 ^* 105.68 ± 2.29 22.40 + - 0.38 0.14 ± 0.00

group Initial weight
(g) Final weight
(g) Weight gain (g) Dietary Intake
(g / day) Dietary efficiency (FER) N 452.13 + - 10.11 556.75 ± 14.87 104.62 + - 4.76 23.97 + - 0.56 0.11 ± 0.00 NS 452.32 + - 9.13 554.32 + - 14.09 102 ± 4.96 22.96 + - 0.45 0.14 + 0.01 ^* HN 474.37 ± 13.51 564.23 + - 14.35 89.86 + - 0.84 21.64 ± 0.45 0.10 ± 0.01 HNS 483.34 + - 4.55 532.12 + 13.18 ^* 48.78 + - 8.63 20.73 + - 0.34 0.10 ± 0.01 HH 487.06 + - 8.90 602.13 + - 12.34 115.07 ± 3.44 21.65 ± 0.39 0.15 ± 0.01 HHS 486.37 + - 8.52 548.39 + - 6.78 ^* 62.02 + - 1.74 21.49 + - 0.37 0.14 ± 0.00

Weight of organ and fatty tissue

The results of weighing liver, kidney and spleen are shown in Tables 5 to 7 in order to examine the effect of green tea on the weight of major organs in the body. Table 5 shows the results of eating the green tea extract as the test extract. Table 6 shows the weight of liver, kidney and spleen in each group consuming the cabbage extract as the test extract and Table 7 as the mixed extract of green tea and cabbage. The weight of the organs was expressed as weight per 100 g of body weight, and there was no significant difference between the normal group and the obesity induction group in the kidney and spleen. However, the liver weight of the HNS group was 2.35 ± 0.03 g and 2.44 ± 0.03 g, respectively. The amount of epididymal fat and kidney fat extracted from the experimental animals is shown in Tables 8 to 10. Table 8 shows the results of intake of the green tea extract as test extract. Table 9 shows the amount of fat extracted from the test extract, and Table 10 shows the amount of fat around the epididymis and kidney fat of each group consuming the mixed extract of green tea and green tea. Many studies have reported that dietary composition, especially fat intake, has a greater effect on body fat accumulation than energy intake. In this study, weights of epididymal fat and kidney fat were increased in obese group. However, the HNS group (2.06 ± 0.12 g / 100 g body weigh) treated with green tea extract in the epididymal fat of the obese group showed a significant decrease compared to the HN group (2.56 ± 0.15 g / 100 g BW) (2.36 ± 0.12 g / 100 g BW) treated with green tea extract was significantly lower than that of HH (2.83 ± 0.18 g / 100 g BW). The dietary intakes of the epididymis were higher in the control and the experimental groups fed the high fat diet than in the normal diet, indicating that the body fat content is closely related to diet. Therefore, the amount of epididymal fat and kidney fat, which are representative of body fat accumulation, was significantly decreased by the administration of green tea extract, indicating that the green tea extract was a very effective material for reducing body fat.

group liver
(g / 100 g BW) kidney
(g / 100 g BW) spleen
(g / 100 g BW) N 2.47 ± 0.06 0.67 ± 0.02 0.19 ± 0.01 NS 2.43 + 0.07 0.65 ± 0.01 0.17 ± 0.01 HN 2.44 ± 0.03 0.59 + - 0.01 0.17 ± 0.01 HNS 2.35 ± 0.03 ^* 0.61 + 0.02 0.18 ± 0.01 HH 2.52 + 0.17 0.56 ± 0.01 0.17 ± 0.01 HHS 2.47 ± 0.06 0.59 + - 0.01 0.16 ± 0.01

group liver
(g / 100 g BW) kidney
(g / 100 g BW) spleen
(g / 100 g BW) N 2.47 ± 0.06 0.67 ± 0.02 0.19 ± 0.01 NS 2.43 + 0.07 0.65 ± 0.01 0.17 ± 0.01 HN 2.44 ± 0.03 0.59 + - 0.01 0.17 ± 0.01 HNS 2.36 ± 0.03 ^* 0.60 + 0.02 0.18 ± 0.01 HH 2.52 + 0.17 0.56 ± 0.01 0.17 ± 0.01 HHS 2.48 ± 0.05 0.57 ± 0.01 0.18 ± 0.01

group liver
(g / 100 g BW) kidney
(g / 100 g BW) spleen
(g / 100 g BW) N 2.47 ± 0.06 0.67 ± 0.02 0.19 ± 0.01 NS 2.43 + 0.07 0.65 ± 0.01 0.17 ± 0.01 HN 2.44 ± 0.03 0.59 + - 0.01 0.17 ± 0.01 HNS 2.33 ± 0.02 ^* 0.61 + 0.02 0.18 ± 0.01 HH 2.52 + 0.17 0.56 ± 0.01 0.17 ± 0.01 HHS 2.38 ± 0.05 0.57 ± 0.01 0.18 ± 0.01

group Epididymal fat mass
(g / 100 g BW) Kidney fat content
(g / 100 g BW) N 2.23 ± 0.19 1.83 + - 0.13 NS 2.13 + - 0.10 1.81 + 0.06 HN 2.56 ± 0.15 2.36 + 0.17 HNS 2.06 ± 0.12 ^* 2.34 ± 0.12 HH 2.81 + 0.14 2.83 ± 0.18 HHS 2.54 + 0.15 2.36 ± 0.12 ^*

group Epididymal fat mass
(g / 100 g BW) Kidney fat content
(g / 100 g BW) N 2.23 ± 0.19 1.83 + - 0.13 NS 2.13 + - 0.10 1.81 + 0.06 HN 2.56 ± 0.15 2.36 + 0.17 HNS 2.18 ± 0.13 ^* 2.34 ± 0.13 HH 2.81 + 0.14 2.83 ± 0.18 HHS 2.62 + 0.13 2.42 ± 0.13 ^*

group Epididymal fat mass
(g / 100 g BW) Kidney fat content
(g / 100 g BW) N 2.23 ± 0.19 1.83 + - 0.13 NS 2.13 + - 0.10 1.81 + 0.06 HN 2.56 ± 0.15 2.36 + 0.17 HNS 1.96 + 0.13 ^* 2.28 ± 0.15 HH 2.81 + 0.14 2.83 ± 0.18 HHS 2.32 + 0.14 2.12 + - 0.12 ^*

Serum GOT  And GPT  Activity measurement

GOT (aspartate aminotransferase) and GPT (alanine aminotransferase) activities in the serum are shown in Tables 11 to 13. Table 11 shows the results of the intake of the green tea extract as the test extract, Table 12 shows the extract of cabbage as the test extract, and Table 13 shows the GOT and GPT activities of each group in which the mixed extract of green tea and cabbage was ingested. GOT and GPT are enzymes that synthesize amino acids in vivo and exist in many organs, but the most abundant of them are enzymes that are widely used as an index of liver damage. The outflow process reduces the energy supply in the cell, and when K ⁺ ions in the cell are released out of the cell, Na ⁺ , Ca ^{2 +,} and moisture are introduced into the cells. As a result, the cells expand and the cell membrane becomes elongated, resulting in GOT and GPT present in the cytoplasm. Therefore, the increase of GOT and GPT in serum indicates the progress of hepatocyte necrosis and hepatic tissue destruction due to hepatotoxicity, and therefore, the degree of free enzyme of these enzymes in the blood is measured and used for the study of hepatotoxicity. As shown in Tables 11 to 13, there was no significant difference between the normal group and the obesity induction group, and it was confirmed that the green tea does not show liver toxicity.

group GPT (mg / dl) GOT (mg / dl) N 30.56 ± 1.49 135.94 ± 5.15 NS 31.50 ± 0.99 118.25 + - 4.52 HN 34.63 ± 4.20 120.75 + - 6.45 HNS 31.69 + 1.35 137.88 + - 6.73 HH 34.00 ± 1.30 124.06 + - 6.64 HHS 40.00 1.00 122.63 + - 8.52

group GPT (mg / dl) GOT (mg / dl) N 30.56 ± 1.49 135.94 ± 5.15 NS 31.25 + - 0.34 118.25 + - 4.52 HN 34.63 ± 4.20 120.75 + - 6.45 HNS 32.34 ± 0.87 132.47 ± 5.67 HH 34.00 ± 1.30 124.06 + - 6.64 HHS 37.45 + - 0.98 126.41 + - 5.43

group GPT (mg / dl) GOT (mg / dl) N 30.56 ± 1.49 135.94 ± 5.15 NS 31.50 ± 0.99 118.25 + - 4.52 HN 34.63 ± 4.20 120.75 + - 6.45 HNS 32.76 ± 2.98 128.79 + - 5.49 HH 34.00 ± 1.30 124.06 + - 6.64 HHS 36.54 ± 2.59 123.54 + - 6.52

Effect on blood lipid composition

Serum triglyceride, total cholesterol, HDL-cholesterol and LDL-cholesterol and glucose levels were analyzed in order to examine the effect of the green tea extract on blood lipid components. The results are shown in Tables 14 to 16. Table 14 shows the results of intake of the green tea extract as the test extract, Table 15 shows the extract of boxwood as the test extract, Table 16 shows the results of the blood triglyceride, total cholesterol, HDL-cholesterol, LDL-cholesterol and glucose levels. Serum triglyceride tended to decrease significantly in both groups (NS, HNS and HHS) fed the green tea extract in both normal (N and NS) and obesity induction groups (HN, HNS, HH and HHS). Serum total cholesterol level in the normal group was significantly lower than that of N group in the NS group, 64.33 ± 1.58 in the HNS group, 64.33 ± 1.58 in the HNS group, 64.42 ± 3.31 in the HN group and 64.42 ± 3.31 in the HN group 69.83 ± 5.05, respectively. Serum HDL-cholesterol levels were significantly increased in the HN and HH groups treated with green tea and HN and HH groups treated with green tea, respectively. HDL-cholesterol is an index of anti-arteriosclerosis, which transports cholesterol from the peripheral blood to the liver, and transports cholesterol in a direction that does not promote atherosclerosis, thereby protecting against coronary heart disease (Gordon, T., Casfelli, WP Hjortland, MC, Kennel, WB and Dawher, TR 1977. High density lipoprotein as a protective factor against coronary heart disease, Framingham study, Am . J. Med . 62: 707.). Therefore, it is thought that green tea increases HDL-cholesterol level and is effective for coronary heart disease. Serum LDL-cholesterol levels were slightly decreased in both the normal group and the obesity-induced group, but there was no significant difference. Blood glucose levels did not show any significant change.

group Triglyceride
(Mg / dl) Total cholesterol
(Mg / dl) HDL-cholesterol
(Mg / dl) LDL-cholesterol
(Mg / dl) Glucose
(Mg / dl) N 92.70 + - 6.52 78.08 + - 5.08 45.33 + - 2.87 17.50 + - 0.88 89.06 + - 2.58 NS 64.33 ± 9.23 ^* 64.64 + 2.84 ^* 39.00 + 2.04 13.33 + - 1.08 88.06 ± 1.50 HN 103.08 ± 10.76 64.42 ± 3.31 33.33 + - 1.10 10.34 ± 2.17 89.94 + - 3.40 HNS 71.75 ± 7.87 ^* 63.20 ± 1.15 37.31 + 1.14 ^* 9.85 ± 1.96 85.75 ± 2.64 HH 101.06 + - 3.16 69.83 + - 5.05 35.08 + - 2.76 8.28 ± 1.34 92.63 + - 1.78 HHS 74.31 + - 7.80 ^* 64.33 + - 1.58 41.93 ± 1.33 ^* 9.78 ± 0.96 95.38 + 2.01

group Triglyceride
(Mg / dl) Total cholesterol
(Mg / dl) HDL-cholesterol
(Mg / dl) LDL-cholesterol
(Mg / dl) Glucose
(Mg / dl) N 92.70 + - 6.52 78.08 + - 5.08 45.33 + - 2.87 17.50 + - 0.88 89.06 + - 2.58 NS 64.33 ± 9.23 ^* 64.64 + 2.84 ^* 39.00 + 2.04 13.33 + - 1.08 88.06 ± 1.50 HN 103.08 ± 10.76 64.42 ± 3.31 33.33 + - 1.10 10.34 ± 2.17 89.94 + - 3.40 HNS 85.90 占 5.78 ^* 63.89 + 1.34 36.21 + - 1.12 ^* 9.97 ± 1.54 86.89 + - 2.53 HH 101.06 + - 3.16 69.83 + - 5.05 35.08 + - 2.76 8.28 ± 1.34 92.63 + - 1.78 HHS 89.21 + - 8.12 ^* 65.54 + - 1.32 39.93 + 1.45 ^* 9.54 ± 1.68 93.21 + 1.98

group Triglyceride
(Mg / dl) Total cholesterol (mg / dl) HDL-cholesterol
(Mg / dl) LDL-cholesterol
(Mg / dl) Glucose
(Mg / dl) N 92.70 + - 6.52 78.08 + - 5.08 45.33 + - 2.87 17.50 + - 0.88 89.06 + - 2.58 NS 64.33 ± 9.23 ^* 64.64 + 2.84 ^* 39.00 + 2.04 13.33 + - 1.08 88.06 ± 1.50 HN 103.08 ± 10.76 64.42 ± 3.31 33.33 + - 1.10 10.34 ± 2.17 89.94 + - 3.40 HNS 65.29 + - 3.59 ^* 61.21 + - 1.05 39.14 + 1.01 ^* 9.19 ± 1.01 84.53 + - 2.34 HH 101.06 + - 3.16 69.83 + - 5.05 35.08 + - 2.76 8.28 ± 1.34 92.63 + - 1.78 HHS 65.03 + - 6.73 ^* 62.24 + 1.43 45.42 占 1.21 ^* 9.18 ± 0.32 92.98 + - 2.32

Atherosclerotic index and cardiac risk index

The atherogenic index and the cardiac risk index were calculated based on the lipid component analysis results of the blood lipid component of the blood lipid component. The results are shown in Tables 17 to 19. Table 17 shows the results of the intake of the green tea extract as the test extract. Table 18 shows the extract of cabbage as the test extract and Table 19 shows the arteriosclerosis index and the cardiac risk index of each group in which the mixed extract of green tea and cabbage was taken . Atherosclerosis index is a value representative of the concentration of neutrophil for high density lipoprotein in the body and cardiac risk index is used as a risk signal for cardiovascular disease. Atherosclerosis and cardiovascular risk are higher in atherosclerosis and cardiovascular disease. The cardiovascular risk index was not significantly different between normal and obese subjects. However, in the arteriosclerosis index, the HHS group (0.63 ± 0.03) treated with green tea extract significantly lowered the HH group (0.73 ± 0.03) than the green tea treated group. As a result, it can be said that the extract of green tea extract reduces the risk of arteriosclerosis.

group Arteriosclerosis index Cardiac risk index N 0.75 ± 0.03 1.75 + 0.03 NS 0.73 + 0.03 1.73 ± 0.03 HN 0.72 + 0.04 1.72 + 0.04 HNS 0.78 ± 0.03 1.78 + 0.03 HH 0.73 + 0.03 1.69 + 0.03 HHS 0.63 + - 0.03 ^* 1.66 + 0.03

group Arteriosclerosis index Cardiac risk index N 0.75 ± 0.03 1.75 + 0.03 NS 0.73 + 0.03 1.73 ± 0.03 HN 0.72 + 0.04 1.72 + 0.04 HNS 0.77 + 0.02 1.78 ± 0.01 HH 0.73 + 0.03 1.69 + 0.03 HHS 0.69 + - 0.03 ^* 1.67 + 0.04

group Arteriosclerosis index Cardiac risk index N 0.75 ± 0.03 1.75 + 0.03 NS 0.73 + 0.03 1.73 ± 0.03 HN 0.72 + 0.04 1.72 + 0.04 HNS 0.73 ± 0.02 1.73 + 0.04 HH 0.73 + 0.03 1.69 + 0.03 HHS 0.57 + - 0.03 ^* 1.63 + 0.03

Blood Leptin  And insulin content measurement

Leptin acts on the hypothalamus to control dietary intake and increases energy expenditure in the peripheral tissues to control obesity. Serum leptin levels are correlated with body fat mass in both animals and humans, and are correlated with body fat mass rather than body weight. Leptin expression is regulated by the amount of fat accumulated in adipose tissue. The blood leptin concentrations are shown in Tables 20 to 22. Table 20 shows the results of ingesting the seaweed extract as a test extract, Table 21 shows the blood leptin and insulin content of each group ingested the extract of the extract as a test extract, Table 22 shows the mixed extract of seaweed and the patch. There was no significant difference between normal group and obese induction group. However, the concentration of leptin in the blood was decreased in both the normal group and the obesity - induced group. It has recently been reported that leptin increases the secretory function of pancreatic insulin. Although there was no significant difference in this experiment, it was confirmed that the expression of insulin was the same as that of leptin. Based on these results, it is concluded that green tea extract has an effect on obesity inhibition.

group Leptin (pg / ml) Insulin (/ / l) N  213.71 + - 24.07 0.74 ± 0.01 NS  165.67 ± 19.53 0.69 ± 0.02 HN  266.06 +/- 47.83 0.76 + 0.04 HNS  171.69 ± 27.87 0.73 + 0.03 HH  350.02 + - 75.60 0.88 ± 0.05 HHS  317.72 ± 37.72 0.86 + 0.04

group Leptin (pg / ml) Insulin (/ / l) N  213.71 + - 24.07 0.74 ± 0.01 NS  165.67 ± 19.53 0.69 ± 0.02 HN  266.06 +/- 47.83 0.76 + 0.04 HNS  189.32 + - 23.27 0.74 + 0.02 HH  350.02 + - 75.60 0.88 ± 0.05 HHS  328.98 ± 45.78 0.86 + 0.02

group Leptin (pg / ml) Insulin (/ / l) N  213.71 + - 24.07 0.74 ± 0.01 NS  165.67 ± 19.53 0.69 ± 0.02 HN  266.06 +/- 47.83 0.76 + 0.04 HNS  158.32 + - 22.34 0.72 ± 0.01 HH  350.02 + - 75.60 0.88 ± 0.05 HHS  302.21 + - 21.45 0.84 + 0.02

Having described the specific part of the present invention in detail, it is apparent to those skilled in the art that such a specific technology is only a preferred embodiment, and the scope of the present invention is not limited thereto. Therefore, the substantial scope of the present invention will be defined by the appended claims and equivalents thereof.

Claims (4)

Salicornia herbacea L.) extracts, paejang (Patrinia scabiosaefolia ) Food composition for improving lipid metabolism disease comprising an extract or a mixture thereof as an active ingredient.
The composition of claim 1, wherein the lipid metabolic disease is obesity, hyperlipidemia, arteriosclerosis or fatty liver.
Pharmaceutical composition for the prevention or treatment of lipid metabolism disease, including a seaweed extract, package extract or a mixture thereof as an active ingredient.
4. The composition of claim 3, wherein the lipid metabolic disease is obesity, hyperlipidemia, arteriosclerosis or fatty liver.